RESI Boston 2026 Agenda Announced: Two Days of Investor Insights, Partnership Strategy, and Networking

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

The agenda for RESI Boston 2026 is here, offering attendees an in-depth look at the conversations shaping the future of early-stage life science investment. Taking place September 22–23 at The Westin Copley Place in Boston, followed by virtual partnering days on September 25, 28, and 29, the expanded two-day in-person conference delivers more opportunities than ever to connect with investors, strategic partners, and industry leaders.

This year’s program reflects the evolving priorities of the healthcare investment ecosystem, with sessions designed to help innovators better understand today’s fundraising environment while building the relationships needed to move their companies forward.

Day one begins by exploring why Boston remains one of the world’s premier biotechnology hubs before examining key topics including partnering with health systems, how venture investors evaluate early-stage therapeutics, securing pharmaceutical partnerships, corporate venture capital strategies, digital health innovation, and the growing influence of family offices in healthcare investing. The day also features the Global Family Office Bioforum (GFOB), an invite-only private networking lunch that brings together select family office investors for high-value discussions and relationship building.

On day two, programming shifts toward emerging investment trends with sessions highlighting angel investing, women’s health, impact investing, and the increasingly important role of mission-driven capital. The conference concludes with two Reverse VC Pitch sessions, where investors take the stage to present directly to entrepreneurs, providing attendees with valuable insight into investment priorities, fund strategies, and what investors are actively seeking in new opportunities. The day also features the exclusive Global VC Connect Lunch, creating another dedicated opportunity for venture capital investors to build meaningful connections.

As always, RESI programming is designed to provide practical insights rather than theory. Whether attendees are preparing for their next fundraising round, pursuing strategic partnerships, or looking to better understand today’s investment landscape, every panel is curated to deliver actionable perspectives from experienced investors and industry leaders.

Combined with RESI’s partnering platform and three additional days of virtual meetings, the conference offers a comprehensive environment for companies seeking to advance fundraising and business development efforts.

Join the RESI Speaker Lineup

Are you an investor or strategic partner with valuable insights to share with early-stage life science companies? We are looking for dynamic speakers to join our RESI panels. Click here to submit your Speaker Interest Form today!

Registration is now open, with super early bird pricing currently available. Companies planning to attend are encouraged to register early to secure the best available rates and begin preparing for one of the most anticipated life science investment events of the year.

Register today and join the global life science investment community at RESI Boston 2026.

Register for RESI Boston

Save the Date – Global Family Office BioForum at RESI Boston – Where Active Investors Connect, Collaborate, and Co-Invest

September 22, 2026 | Westin Copley Place | RESI Boston

By Joey Wong, Director of Investor Research, Hong Kong BD, LSN

Joey-New-Headshot

Life Science Nation (LSN) is pleased to announce the formal program for the Global Family Office BioForum (GFOB) and invites qualified family office investors to participate in this exclusive gathering.

Held during the Redefining Early-Stage Investments (RESI) Conference on Tuesday, September 22, at the Westin Copley Place in Boston, GFOB provides a private, curated environment for family offices to:

  • Exchange strategies across asset classes and investment themes
  • Share deal flow insights and emerging biotech opportunities
  • Explore co-investment partnerships in early-stage therapeutics and healthcare innovation

In addition to the private luncheon and networking session, GFOB will feature a Family Office Investors Panel open to all RESI attendees. The panel will spotlight perspectives from seasoned family office investors who are actively deploying capital in the life sciences and healthcare sectors.

If you are a Family Office and would like to attend the Family Office BioForum Luncheon

RSVP for GFOB Here

Only active family office investors will be accepted.

Register for RESI Boston 2026
Secure your ticket and access over 500 investors across family offices, venture capital, pharma, and strategic partners.

Register for RESI Boston

More Connections, Better Matches: Inside RESI San Diego’s 1,000+ Investor Meeting Success

By Sougato Das, President and COO, LSN

Sougato-Das

RESI San Diego was a powerhouse gathering of 300+ active early-stage life science investors including VCs, angels, family offices, CVCs, venture philanthropy, and pharma external innovation scouts across 10 distinct categories.

What made this event truly remarkable wasn’t just the sheer number of attendees, but their high level of engagement. Throughout the five-day hybrid conference, innovators and capital providers initiated thousands of high-value conversations, reinforcing why RESI remains a premier venue for early-stage companies seeking Seed, Series A, and Series B financing.

RESI San Diego: Partnering Success by the Numbers
The event saw incredible partnering activity, showcasing both high volume and improved precision:

  • 11,000+ Partnering requests submitted.
  • 1,400+ Accepted meetings.

This jump in efficiency reflects a growing emphasis on targeted outreach and thoughtful meeting selection, helping attendees spend less time chasing cold leads and more time speaking with organizations that closely match their technology and fundraising goals.

Furthermore, the hybrid format delivered maximum flexibility.

The RESI Differentiator: Why Our Matches are Stronger
Other industry conferences often suffer from half-empty investor profiles, making it incredibly difficult for fundraising startups to know whom to target. RESI is built differently.

  • Vetted, Highly-Detailed Profiles: Our dedicated Investor Research Team manually populates and verifies every single investor profile in the system. You get the exact detail you need to determine if an investor is a legitimate fit.
  • No “Undercover” Service Providers: Our team meticulously screens every participant to ensure that anyone registered as an investor is actually a legitimate capital provider ready to invest, not financial service providers in disguise.
  • High Visibility on Site: With investors easily identified by their red registration badges, initiating spontaneous, high-value conversations during in-person days was easier than ever.

Maintain Your Fundraising Momentum
Fundraising is a relationship-driven process. The strongest outcomes rarely come from a single meeting; they are built through multiple touchpoints over time. Participating in sequential RESI conferences allows you to strengthen existing relationships, introduce new data milestones, and refine your pitch.

Super Early Bird registration is now open for our upcoming landmark events:

  • RESI Boston (September 2026): Held during Biotech Week Boston, featuring 2 days of expanded in-person programming and 3 days of virtual partnering. (Save $300 if you register by this Friday, July 17!)
  • RESI JPM 2027 (January 2027): Returning to San Francisco during JPM Healthcare Week, the busiest week in healthcare venture capital. 2 days of live networking at the SF Marriott Marquis, followed by 3 days of global virtual partnering.

Lock in the lowest rates of the season today, secure your Super Early Bird pricing, and keep your fundraising momentum moving forward!

Register for RESI Boston Register for RESI JPM

Registration Now Open for RESI JPM 2027 

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

Life Science Nation is excited to announce that registration is now open for RESI JPM 2027, taking place January 11–12 at the San Francisco Marriott Marquis, followed by three days of virtual partnering on January 13, 18, and 19. 

Held alongside the world’s largest gathering of healthcare investors, executives, and innovators during JPM Week, RESI JPM provides early-stage life science companies with a unique opportunity to raise capital, build strategic partnerships, and accelerate business development in one of the industry’s most active networking environments. 

Previous RESI JPM conferences welcomed more than 1,000 attendees, including over 600 active investors, strategic partners, pharmaceutical business development professionals, and industry leaders. The conference combines curated educational programming with one-on-one partnering meetings, creating meaningful opportunities for fundraising companies to connect directly with the investors and partners best aligned with their technologies. 

The expanded format begins with two full days of in-person programming at the San Francisco Marriott Marquis, featuring investor panels, educational workshops, the Innovator’s Pitch Challenge, networking events, poster presentations, and partnering meetings. The conference then continues online with three additional days of virtual partnering, allowing participants to maximize the number of meetings they can schedule while extending networking opportunities beyond the in-person event. 

Whether you are seeking Seed, Series A, or Series B financing, exploring strategic partnerships, licensing opportunities, or looking to expand your visibility within the life science investment community, RESI JPM offers multiple ways to engage. Registration options are available for startups, fundraising executives, service providers, technology hubs, exhibitors, and qualified investors. 

Early Bird registration is now available, offering substantial savings on five-day hybrid registration for startups and fundraising executives. Register early to lock in the lowest available rates. 

Organizations looking to maximize their visibility during JPM Week can also take advantage of sponsorship and exhibition opportunities designed to connect brands with a highly targeted audience of investors, innovators, and industry leaders. 

Register today and save up to $900 with Super Early Bird pricing!

Register Now

Don’t miss your opportunity to be part of one of the life science industry’s premier fundraising and partnering events. 

Accelerate Your Fundraising with Life Science Nation’s BD Assist 

By Sougato Das, President and COO, LSN

Sougato-Das

Raising capital is rarely about finding more investors. It’s about finding the right investors, telling the right story, and consistently building relationships that lead to meaningful opportunities. Additionally and importantly, it is about having a dedicated resource that finds those investors, reaches out to them regularly, and secures meetings with them.

Life Science Nation’s BD Assist program was created to help early-stage life science companies do exactly that by making Life Science Nation into that dedicated resource.

BD Assist is LSN’s premier business development program, providing startups with an experienced team dedicated to advancing their fundraising and partnering efforts throughout the year. Designed for companies seeking investment, licensing opportunities, or strategic collaborations, the program combines targeted investor research, strategic messaging, personalized outreach, and ongoing business development support into one comprehensive solution.

Every engagement begins by refining the company’s investment narrative and marketing materials to ensure they clearly communicate the value of the technology, market opportunity, and growth strategy. From there, Life Science Nation identifies and prioritizes a highly targeted global audience of investors and strategic partners whose interests align with the company’s stage, therapeutic area, and business objectives.

With the strategy in place, LSN launches and manages a personalized outreach campaign on the company’s behalf, tracking every interaction through the client’s CRM platform. Outreach is continuously refined based on engagement, allowing companies to build momentum over time while maintaining visibility with investors and corporate partners actively seeking new opportunities.

Clients also benefit from regular strategy discussions, ongoing campaign optimization, and access to Life Science Nation’s extensive global investor ecosystem. For companies participating in RESI conferences, BD Assist extends that support by managing partnering activities and helping maximize high-value meeting opportunities throughout the event.

Unlike traditional consulting services that provide recommendations, BD Assist becomes an extension of your business development team. LSN handles the day-to-day execution so your leadership can remain focused on advancing the science, growing the business, and preparing for meaningful investor conversations.

Whether you are preparing for your first institutional raise, expanding into new markets, or pursuing strategic partnerships, BD Assist provides the expertise, infrastructure, and execution to help accelerate your fundraising journey.

If your goal is to spend less time searching for investors and more time building relationships with the right ones, BD Assist was built for you.

Ready to activate your global roadshow? Click here to fill out the LSN Labs company assessment report and we’ll be in touch with you soon.

Click Here to Fill Out the LSN Labs Company Assessment Report

KBIC Japan Life Science Showcase Strengthens Cross-Border Partnerships at RESI San Diego

By Momo Yamamoto, Senior Investor Research Analyst, LSN

The KBIC Japan Life Science Showcase brought together Japanese innovators, investors, corporate leaders, and government representatives during RESI San Diego to highlight emerging technologies and strengthen collaboration between Japan and the global life science community. As Japan’s largest biomedical cluster and title sponsor of the RESI Conference, the Kobe Biomedical Innovation Cluster (KBIC) brings together approximately 350 companies, medical institutions, and research organizations advancing healthcare innovation. The showcase featured eight Japanese startups selected for their readiness to engage with international investors and licensing partners, providing a platform to introduce their technologies to a global audience.

Each startup delivered a six-minute company presentation followed by five minutes of live Q&A in front of investor judges, giving attendees the opportunity to explore each company’s science, commercialization strategy, and market potential through direct discussions with the founders. The showcase featured an accomplished panel of judges representing Alumni Ventures, Aquillius Ventures, Bristol Myers Squibb, JLABS (Johnson & Johnson), and Mass Medical Angels. Drawing expertise across venture capital, corporate innovation, and early-stage investing, the judges engaged founders with thoughtful questions and constructive feedback, creating meaningful dialogue throughout the session.

Complementing the startup presentations, representatives from JIC Venture Growth Investments and Japan’s Ministry of Economy, Trade and Industry (METI) shared insights into Japan’s evolving venture capital landscape, government initiatives supporting innovation, and the future outlook for the country’s startup ecosystem. Their presentations provided valuable context for international investors interested in partnering with Japanese life science companies.

More than a series of company presentations, the KBIC Japan Life Science Showcase demonstrated the growing momentum behind cross-border collaboration in life sciences. By connecting Japan’s innovative startup ecosystem with U.S. and international investors, strategic partners, and industry leaders, the session reinforced a shared commitment to accelerating healthcare innovation through global partnerships. Events like these continue to strengthen the bridge between regional ecosystems, creating new opportunities for investment, licensing, and commercialization that benefit both the Japanese and international life science communities.

Hot Investor Mandate: Early-Stage Focused Fund Invests in Seed to Series A Rounds in Digital Health and Healthtech Companies

The firm is an early-stage venture capital firm headquartered in Europe and currently investing from its second fund. The firm focuses on startups with proprietary technology and strong global growth potential across deeptech, future of work, fintech, healthtech, and digital health. The firm typically invests in Seed and Series A rounds, generally leading financings while also participating as a syndicate or co-investor when appropriate. Typical investment sizes range from approximately €700K to €1.5M. While the firm invests internationally, companies with connections to the Southeastern European region are viewed favorably.

The firm focuses on healthtech and digital health companies developing software-driven healthcare solutions. The firm is agnostic across healthcare subsectors and disease areas, provided the technology is primarily software-based and demonstrates meaningful innovation, scalability, and commercial potential.

From a company and management team perspective, the firm does not impose strict requirements but values founders with deep domain expertise, strong technological differentiation, and defensible intellectual property. Companies with ties to the Southeastern European ecosystem are considered a plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com